TABLE 2.
Percentage With Late Effects in Each System by Clinical Trial Participation and Tumor Type
| ALL N = 304 | AML N = 48 | RMS N = 64 | NB N = 12 | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||
| On Trial | Off Trial | On Trial | Off Trial | On Trial | Off Trial | On Trial | Off Trial | |
| CNS | 5.9 | 6.6 | 4.2 | 0.0 | 0.0 | 3.1 | 0.0 | 16.7 |
| Auditory | 4.6 | 0.7 | 8.3 | 12.5 | 3.2 | 3.1 | 50.0 | 33.3 |
| Eye/visual | 5.3 | 2.6 | 12.5 | 4.2 | 12.5 | 15.6 | 0.0 | 0.0 |
| Cognitive | 10.5 | 11.2 | 8.3 | 0.0 | 6.3 | 6.3 | 16.7 | 33.3 |
| Endocrine | 21.1 | 18.4 | 20.8 | 16.7 | 12.5 | 6.3 | 16.7 | 50.0 |
| Cardiac | 4.6 | 4.6 | 12.5 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Secondary neoplasms | 0.7 | 1.3 | 0.0 | 0.0 | 9.4 | 9.4 | 0.0 | 0.0 |
| Psychological | 5.9 | 8.6 | 4.2 | 12.5 | 3.1 | 9.4 | 0.0 | 16.7 |
| GI/GU | 3.9 | 1.3 | 4.2 | 16.7 | 0.0 | 3.1 | 0.0 | 16.7 |
| Gynecologic | 0.0 | 0.0 | 4.2 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Musculoskeletal | 20.4 | 19.7 | 4.2 | 8.3 | 21.9 | 25.0 | 7.1 | 16.7 |
| Dental | 0.0 | 0.7 | 0.0 | 0.0 | 3.1 | 6.3 | 0.0 | 16.7 |
| Kidney | 2.0 | 0.7 | 8.3 | 16.7 | 0.0 | 0.0 | 0.0 | 16.7 |
| Chronic GVHD | 0.7 | 2.0 | 8.3 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 |
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CNS, central nervous system; GI, gastrointestinal; GU, genitourinary; GVHD, graft-versus-host disease; NB, neuroblastoma; RMS, rhabdomyosarcoma.
The median number of clinical systems that incurred a late effect across all tumor types was 1 (range, 0–5) for both subjects treated on trial and off trial with standard therapy.